These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28279082)

  • 1. Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury.
    Mak A; Johnston A; Uetrecht J
    J Immunotoxicol; 2017 Dec; 14(1):89-94. PubMed ID: 28279082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of CD8 T Cells in Amodiaquine-Induced Liver Injury in PD1-/- Mice Cotreated with Anti-CTLA-4.
    Mak A; Uetrecht J
    Chem Res Toxicol; 2015 Aug; 28(8):1567-73. PubMed ID: 26154582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Immune Modulators on Amodiaquine-Induced Liver Injury.
    Mak A; Cho TE; Uetrecht J
    Chem Res Toxicol; 2018 Aug; 31(8):739-744. PubMed ID: 29938495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
    Mak A; Kato R; Weston K; Hayes A; Uetrecht J
    Toxicol Sci; 2018 Feb; 161(2):412-420. PubMed ID: 29087505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients.
    Metushi IG; Hayes MA; Uetrecht J
    Hepatology; 2015 Apr; 61(4):1332-42. PubMed ID: 25283142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury.
    Mak A; Uetrecht J
    J Immunotoxicol; 2015; 12(4):361-7. PubMed ID: 25425471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of an animal model to test whether non-alcoholic fatty liver disease increases the risk of idiosyncratic drug-induced liver injury.
    Mak A; Cho T; Uetrecht J
    J Immunotoxicol; 2018 Dec; 15(1):90-95. PubMed ID: 29733743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset.
    Metushi IG; Cai P; Dervovic D; Liu F; Lobach A; Nakagawa T; Uetrecht J
    J Immunotoxicol; 2015; 12(3):247-60. PubMed ID: 25046026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of CCL2/CCR2 macrophage recruitment in amodiaquine-induced liver injury.
    Mak A; Uetrecht J
    J Immunotoxicol; 2019 Dec; 16(1):28-33. PubMed ID: 30663942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury.
    Mak A; Uetrecht J
    Chem Res Toxicol; 2015 Dec; 28(12):2287-91. PubMed ID: 26529122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring an animal model of amodiaquine-induced liver injury in rats and mice.
    Liu F; Cai P; Metushi I; Li J; Nakayawa T; Vega L; Uetrecht J
    J Immunotoxicol; 2016 Sep; 13(5):694-712. PubMed ID: 27416278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Injury Caused by Green Tea Extract in PD-1
    Cho T; Wang X; Yeung K; Cao Y; Uetrecht J
    Chem Res Toxicol; 2021 Mar; 34(3):849-856. PubMed ID: 33617238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune mechanisms of idiosyncratic drug-induced liver injury.
    Mak A; Uetrecht J
    J Clin Transl Res; 2017 Feb; 3(1):145-156. PubMed ID: 30873473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing Possible Risk Factors for Idiosyncratic Drug-Induced Liver Injury Using an Amodiaquine Mouse Model and Co-treatment with 1-Methyl-d-Tryptophan or Acetaminophen.
    Cho T; Kok LY; Uetrecht J
    ACS Omega; 2021 Feb; 6(7):4656-4662. PubMed ID: 33644572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid-induced liver injury and immune response in mice.
    Metushi IG; Uetrecht J
    J Immunotoxicol; 2014 Oct; 11(4):383-92. PubMed ID: 24303880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
    van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
    Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of idiosyncratic drug-induced liver injury.
    Uetrecht J
    Adv Pharmacol; 2019; 85():133-163. PubMed ID: 31307585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges.
    Jee A; Sernoskie SC; Uetrecht J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications.
    Dara L; Liu ZX; Kaplowitz N
    Liver Int; 2016 Feb; 36(2):158-65. PubMed ID: 26484420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury.
    Woodhead JL; Watkins PB; Howell BA; Siler SQ; Shoda LKM
    Drug Metab Pharmacokinet; 2017 Feb; 32(1):40-45. PubMed ID: 28129975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.